Module

First-Line and Second-Line Treatment of Advanced Non-Small-Cell Lung Cancer

Source: Research Priorities in Non-Small-Cell Lung Cancer

First-Line and Second-Line Treatment of Advanced Non-Small-Cell Lung Cancer

Faculty:
Fred R. Hirsch, MD, PhD

CME CREDIT INFORMATION

Release Date: 02/27/07

Expiration Date: 02/26/08

Physicians: maximum of 0.75 AMA PRA Category 1 Credit(s)™

Registered Nurses: 0.9 Nursing CE credit

Status: Please log in to view status

Learning Objectives

Upon completion of this activity, participants should be able to:

Review clinical trial results of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of NSCLC
Describe future therapeutic approaches to NSCLC
Summarize the use of bevacizumab and cetuximab in the treatment of advanced NSCLC

Topics covered include:

Epidemiology of Advanced NSCLC
Current Standard Treatment for Patients With Advanced Disease
Targeted Agents for the First-Line Treatment of NSCLC
Optimizing Patient Selection
Second-Line Treatment Options for Advanced NSCLC
Unanswered Questions Regarding the Second-Line Treatment of Metastatic NSCLC
Targeted Therapies for the Second-Line Treatment of NSCLC
Future Trials
Conclusions
Research Priorities in the Treatment of Metastatic NSCLC

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.